Interventional Spine's Technology Enhances DePuy Synthes
Portfolio of Open and Minimally Invasive Spine Surgery Solutions
RAYNHAM, Mass., Jan. 3, 2017 /PRNewswire/
-- DePuy Synthes Products, Inc., part of the Johnson & Johnson Family
of Companies, announced today an asset purchase and development agreement with
Interventional Spine, Inc., a privately held manufacturer of expandable cageand minimally invasive surgery (MIS) technologies for spinal fusion. The
Interventional Spine agreement is the latest example of the Johnson &
Johnson Medical Devices strategy of investing in innovation in key platforms
that will drive future growth. Financial terms of the transaction have not been
disclosed.
With Interventional Spine's technology, DePuy Synthes will
add a family of expandable cages, which are used in spinal fusion surgery to
restore the natural disc height, to the company's core spine platform.
Interventional Spine's expandable cage technology provides optimal tactile feedback
for the surgeon, and features a continuously adjustable design that allows the
surgeon to customize the device height to the patient's anatomy. The implants
are designed to maximize bone graft contact and containment, which helps
promote bone growth and fusion. DePuy Synthes will significantly expand access
to this technology by leveraging its global sales network. Interventional Spine
currently serves healthcare professionals in the United States and
select international markets.
"DePuy Synthes and Interventional Spine have a common
goal—advancing spinal care for patients with debilitating degenerative disc
disease and expanding access to this important technology globally," said
Ciro Römer, Company Group Chairman, DePuy Synthes. "Through this collaboration
with Interventional Spine, we will broaden our product offering in a strategic
platform and reach more customers and patients around the world."
DePuy Synthes is also acquiring Interventional Spine's facet
screw system for open and percutaneous spine surgery, a type of MIS that uses
small skin incisions without cutting the underlying muscle, which can help
reduce the risk of complications and improve outcomes in spinal fusion surgery.1
DePuy Synthes has the second largest spine business in the
world with a broad portfolio of spinal care solutions, including treatments for
aging spine, less invasive surgery, scoliosis, degenerative disc disease, care
delivery innovation and enabling technologies.
About DePuy Synthes Companies
DePuy Synthes Companies, part of the Johnson & Johnson Family of Companies,
provides one of the most comprehensive orthopaedics portfolios in the
world. DePuy Synthes Companies solutions, in specialties including joint
reconstruction, trauma, craniomaxillofacial, spinal surgery and sports
medicine, are designed to advance patient care while delivering clinical and
economic value to health care systems worldwide. For more information,
visit www.depuysynthes.com.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking
statements" as defined in the Private Securities Litigation Reform Act of
1995 related to an acquisition of assets and development of Interventional
Spine's expandable cage and minimally invasive surgery technologies. The reader
is cautioned not to rely on these forward-looking statements. These statements
are based on current expectations of future events. If underlying assumptions
prove inaccurate or known or unknown risks or uncertainties materialize, actual
results could vary materially from the expectations and projections of DePuy
Synthes Products, Inc., the DePuy Synthes Companies and/or Johnson &
Johnson. Risks and uncertainties include, but are not limited to: challenges related
to integrating Interventional Spine's products and technologies and ensuring
their continued performance and market growth; the potential that the expected
benefits and opportunities related to the transaction may not be realized or
may take longer to realize than expected; challenges inherent in product
development, including the uncertainty of clinical outcomes and commercial
success; competition, including technological advances, new products and
patents attained by competitors; the ability of DePuy Synthes to successfully
execute strategic plans; challenges to patents; changes to applicable laws and
regulations, including tax laws; changes in behavior and spending patterns of
purchasers of health care products and services; global health care reforms and
trends toward health care cost containment. A further list and description of
these risks, uncertainties and other factors can be found in Johnson &
Johnson's Annual Report on Form 10-K for the fiscal year ended January 3,
2016, including in Exhibit 99 thereto, and the company's subsequent filings
with the Securities and Exchange Commission. Copies of these filings are
available online at www.sec.gov, www.jnj.com or on request
from Johnson & Johnson. The DePuy Synthes Companies and Johnson &
Johnson do not undertake to update any forward-looking statement as a result of
new information or future events or developments.
The third party trademarks used herein are the trademarks of
their respective owners.
©DePuy Synthes 2017. All rights reserved.
1 Barbagallo, G. et al. Percutaneous minimally invasive
versus open spine surgery in the treatment of fractures of the thoracolumbar
junction: a comparative effectiveness review. Evidence-Based Spine-Care
Journal. Volume 3/Issue 3 (2012): 43-49.
Published at PRNewsWire
No comments:
Post a Comment